Equities analysts forecast that Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) will post earnings of ($0.90) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Rhythm Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.71) and the lowest estimate coming in at ($1.06). Rhythm Pharmaceuticals posted earnings per share of ($0.74) during the same quarter last year, which indicates a negative year over year growth rate of 21.6%. The firm is expected to announce its next earnings results on Friday, March 13th.
On average, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($3.93) per share for the current year, with EPS estimates ranging from ($4.19) to ($3.52). For the next financial year, analysts anticipate that the firm will post earnings of ($3.41) per share, with EPS estimates ranging from ($4.05) to ($3.06). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Friday, November 1st. The company reported ($1.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.02.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DekaBank Deutsche Girozentrale bought a new stake in shares of Rhythm Pharmaceuticals in the 2nd quarter worth approximately $564,000. Susquehanna International Group LLP bought a new stake in shares of Rhythm Pharmaceuticals in the 2nd quarter worth approximately $328,000. Rice Hall James & Associates LLC raised its holdings in shares of Rhythm Pharmaceuticals by 172.5% in the 2nd quarter. Rice Hall James & Associates LLC now owns 63,217 shares of the company’s stock worth $1,391,000 after purchasing an additional 40,015 shares in the last quarter. Fosun International Ltd raised its holdings in shares of Rhythm Pharmaceuticals by 37.0% in the 2nd quarter. Fosun International Ltd now owns 40,720 shares of the company’s stock worth $883,000 after purchasing an additional 11,000 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Rhythm Pharmaceuticals by 2.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 126,835 shares of the company’s stock worth $2,751,000 after purchasing an additional 3,057 shares in the last quarter. Institutional investors and hedge funds own 90.57% of the company’s stock.
Shares of NASDAQ:RYTM traded up $0.11 during trading on Thursday, reaching $21.50. 126,300 shares of the company’s stock traded hands, compared to its average volume of 174,771. The company has a 50 day moving average of $21.67 and a 200-day moving average of $22.57. The stock has a market capitalization of $943.98 million, a P/E ratio of -9.00 and a beta of 0.63. Rhythm Pharmaceuticals has a 12 month low of $18.00 and a 12 month high of $32.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.78 and a quick ratio of 7.80.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.
Featured Article: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.